Sionna Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing small molecule therapies that directly stabilize the nucleotide binding domain 1 (NBD1) of the CFTR protein to address the prevalent F508del mutation in cystic fibrosis. Since inception in 2019, the company has incurred significant operating losses driven by extensive R&D investments but maintains a strong liquidity position. In 2025, positive Phase 1 trial results supported advancement into Phase 2a studies. The firm's proprietary approach offers potential differentiation versus incumbent modulators, but substantial clinical and regulatory risks remain along with financial uncertainties as commercialization capabilities are still developing.